Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy. …
FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News -
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Novo Nordisk appoints Michael Azrak as new Oceania General Manager
December 1, 2025 - - Latest News -
New PBS listing brings immunotherapy option to Australians with rare head and neck cancer
December 1, 2025 - - Latest News -
DBG Health appoints Matt Zeller to lead Arrotex Pharmaceuticals into its next phase of growth
December 1, 2025 - - Latest News -
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 - - Australian Biotech -
Melbourne showcases its health and biomedical strength as leaders gather for National Precincts Summit
December 1, 2025 - - Australian Biotech